You have 9 free searches left this month | for more free features.

City

Beijing (1)

Shanghai (1)

Condition

Advanced Salivary Gland Carcinoma (1)

Advanced Solid Tumours (1)

Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma (1)

Neoadjuvant or Conversion Therapy (1)

Precision Therapy (1)

Overall Status

Not yet recruiting (2)

Recruiting (1)

Sign in for free

Phase

phase 2 (2)

phase 1 (1)

Sponsor

Fudan University (1)

Peking Union Medical College (1)

Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1)

Collaborator

Peking University Hospital of Stomatology (1)

Intervention

shr-a1921 (3)

albumin paclitaxel with platinum (1)

antiandrogen drug treatment (1)

larotinib or enttraitinib (1)

shr 3680 + leuprolide (1)

shr-a1811 (1)

small molecule multi-target tyrosine kinase inhibitors (1)

vedolizumab (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (3)

shr-a1921

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Advanced Solid Tumours Trial (SHR-A1921)

Not yet recruiting

Advanced Solid Tumours

SHR-A1921

(no location specified)

Nov 29, 2021

Advanced Salivary Gland Carcinoma Trial in Shanghai (SHR-A1811, SHR 3680 + leuprolide, SHR-A1921)

Not yet recruiting

Advanced Salivary Gland Carcinoma

SHR-A1811
+2 more

Shanghai, China

Dongmei Ji

Jun 21, 2023

Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy Trial in

Recruiting

Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma
+2 more

Vedolizumab
+5 more

Beijing, Beijing, China
+1 more

Nov 21, 2023